1c:{"metadata":[["$","title","0",{"children":"NIH VideoCast - Pediatric Ontogeny: Ready for Incorporation into Modeling in Pediatric Drug Development?"}],["$","meta","1",{"name":"description","content":"Modeling and simulation can reduce the numbers of pediatric patients to predict drug dose and effect, but such predictions rely on solid information on the ontogeny of the systems that interact with the new drug.\nThe objectives of this workshop are to:\n

\n1.\tReview the present state of knowledge of the ontogeny of systems critical to drug dosing and effect in pediatric patients.\n

\n2.\tDiscuss whether our knowledge of ontogeny of specific systems is adequate at the present time to make pediatric dosing and effect predictions through modeling and simulation.\n

\n3.\tIdentify pathways forward for acquiring the additional information needed for incorporating ontogeny into modeling and simulation predictions for pediatric new drug development.\n"}],["$","meta","2",{"name":"publisher","content":"National Institutes of Health"}],["$","meta","3",{"property":"og:title","content":"NIH VideoCast - Pediatric Ontogeny: Ready for Incorporation into Modeling in Pediatric Drug Development?"}],["$","meta","4",{"property":"og:description","content":"Modeling and simulation can reduce the numbers of pediatric patients to predict drug dose and effect, but such predictions rely on solid information on the ontogeny of the systems that interact with the new drug.\nThe objectives of this workshop are to:\n

\n1.\tReview the present state of knowledge of the ontogeny of systems critical to drug dosing and effect in pediatric patients.\n

\n2.\tDiscuss whether our knowledge of ontogeny of specific systems is adequate at the present time to make pediatric dosing and effect predictions through modeling and simulation.\n

\n3.\tIdentify pathways forward for acquiring the additional information needed for incorporating ontogeny into modeling and simulation predictions for pediatric new drug development.\n"}],["$","meta","5",{"property":"og:url","content":"https://uat.d1rkikwu4q8tg.amplifyapp.com/watch/b8fff516-d5db-11f0-9cf9-12c45c580ad9"}],["$","meta","6",{"property":"og:site_name","content":"NIH VideoCast"}],["$","meta","7",{"property":"og:image","content":"https://nihcit.rev.vbrick.com/api/v2/media/videos/thumbnails/63dabaa4-19c7-45cf-82ec-911c47f020e9.jpg"}],["$","meta","8",{"property":"og:type","content":"website"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"NIH VideoCast - Pediatric Ontogeny: Ready for Incorporation into Modeling in Pediatric Drug Development?"}],["$","meta","11",{"name":"twitter:description","content":"Modeling and simulation can reduce the numbers of pediatric patients to predict drug dose and effect, but such predictions rely on solid information on the ontogeny of the systems that interact with the new drug.\nThe objectives of this workshop are to:\n

\n1.\tReview the present state of knowledge of the ontogeny of systems critical to drug dosing and effect in pediatric patients.\n

\n2.\tDiscuss whether our knowledge of ontogeny of specific systems is adequate at the present time to make pediatric dosing and effect predictions through modeling and simulation.\n

\n3.\tIdentify pathways forward for acquiring the additional information needed for incorporating ontogeny into modeling and simulation predictions for pediatric new drug development.\n"}],"$L22","$L23","$L24"],"error":null,"digest":"$undefined"}